WHO Withdrawal Cuts US Researchers Off from Global Health Networks
March 14, 2026 · 2 min read
Arthur Griffin
The United States officially completed its withdrawal from the World Health Organization on January 22, 2026, one year after President Trump announced the departure. The CDC confirmed that all WHO funding has been halted, all CDC personnel withdrawn from WHO postings, and activities redirected to bilateral country-to-country engagement.
What Research Networks Are at Stake
The withdrawal severs American researchers from WHO-coordinated platforms that have underpinned decades of scientific collaboration. The Global Influenza Surveillance and Response System, international clinical trial consortia, and pathogen sample-sharing frameworks all depend on multilateral participation. US scientists who relied on these systems for real-time epidemiological data and biological materials now face potential delays in accessing outbreak information — gaps that could extend vaccine development timelines by months.
The International Agency for Research on Cancer (IARC), a WHO specialized agency headquartered in Lyon, France, has long partnered with NCI and NIH-funded researchers on global cancer studies. The NCI has provided over $5.6 million in grants supporting IARC projects in recent years — funding now in jeopardy as the administration bars federal agencies from engaging with WHO entities. For rare diseases and pediatric cancers, where international collaboration is essential because individual countries lack sufficient patient populations, the consequences could be severe.
Contingency Plans and Alternative Pathways
Scientists are already drawing up contingency plans. Individual researchers will likely maintain collegial relationships with international peers, but individual-level contact cannot replace the coordination and institutional weight of federal-level participation. The administration has stated it will pursue global health objectives through "direct bilateral engagements" rather than multilateral WHO coordination.
For cancer researchers and global health investigators whose work depends on multinational data sets or cross-border clinical trials, the immediate task is identifying alternative funding sources and partnership structures outside the WHO framework. Some Commonwealth nations are reportedly expanding their participation in WHO research networks to fill the gap left by the US.
Researchers navigating these disruptions can find analysis of how federal policy shifts affect grant funding on the Granted blog.